Literature DB >> 26223247

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P Baas1, D Fennell2, K M Kerr3, P E Van Schil4, R L Haas5, S Peters6.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26223247     DOI: 10.1093/annonc/mdv199

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  87 in total

1.  MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.

Authors:  Sophia F Magkouta; Apostolos G Pappas; Photene C Vaitsi; Panagiotis C Agioutantis; Ioannis S Pateras; Charalampos A Moschos; Marianthi P Iliopoulou; Chrysavgi N Kosti; Heleni V Loutrari; Vassilis G Gorgoulis; Ioannis T Kalomenidis
Journal:  JCI Insight       Date:  2020-06-18

2.  A case from India of pleural malignant mesothelioma probably due to domestic and environmental asbestos exposure: a posthumous report.

Authors:  Venkiteswaran Muralidhar; Pankaja Raghav; Prianka Das; Akhil Goel
Journal:  BMJ Case Rep       Date:  2019-03-31

3.  Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.

Authors:  A Botticella; G Defraene; K Nackaerts; C Deroose; J Coolen; P Nafteux; B Vanstraelen; S Joosten; L A W Michiels; S Peeters; D De Ruysscher
Journal:  Strahlenther Onkol       Date:  2017-02-14       Impact factor: 3.621

Review 4.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

Review 5.  Optimal Therapy of Advanced Stage Mesothelioma.

Authors:  Maria M J Disselhorst; Sjaak J A Burgers; Paul Baas
Journal:  Curr Treat Options Oncol       Date:  2017-08

6.  Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.

Authors:  Ori Wald; David J Sugarbaker
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

7.  Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial.

Authors:  Pyng Lee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 8.  Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.

Authors:  Charlotte De Bondt; Ioannis Psallidas; Paul E Y Van Schil; Jan P van Meerbeeck
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 9.  Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

Authors:  Paul Halford; Amelia O Clive
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 10.  Current chemotherapy strategies in malignant pleural mesothelioma.

Authors:  Cornedine Jannette de Gooijer; Paul Baas; Jacobus Adrianus Burgers
Journal:  Transl Lung Cancer Res       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.